SK285665B6 - Kryštalické makrolidy, spôsob ich prípravy, farmaceutický prostriedok a ich použitie - Google Patents

Kryštalické makrolidy, spôsob ich prípravy, farmaceutický prostriedok a ich použitie Download PDF

Info

Publication number
SK285665B6
SK285665B6 SK1866-99A SK186699A SK285665B6 SK 285665 B6 SK285665 B6 SK 285665B6 SK 186699 A SK186699 A SK 186699A SK 285665 B6 SK285665 B6 SK 285665B6
Authority
SK
Slovakia
Prior art keywords
compound
formula
crystalline
solution
solvent
Prior art date
Application number
SK1866-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK186699A3 (en
Inventor
Cornelia Dosenbach
Maximilian Grassberger
Otto Hartmann
Amarylla Horvath
Jean-Paul Mutz
Gerhard Penn
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10815103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285665(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK186699A3 publication Critical patent/SK186699A3/sk
Publication of SK285665B6 publication Critical patent/SK285665B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1866-99A 1997-06-30 1998-06-26 Kryštalické makrolidy, spôsob ich prípravy, farmaceutický prostriedok a ich použitie SK285665B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713730.1A GB9713730D0 (en) 1997-06-30 1997-06-30 Organic compounds
PCT/EP1998/003929 WO1999001458A1 (fr) 1997-06-30 1998-06-26 Macrolides cristallins et procede de preparation associe

Publications (2)

Publication Number Publication Date
SK186699A3 SK186699A3 (en) 2000-05-16
SK285665B6 true SK285665B6 (sk) 2007-05-03

Family

ID=10815103

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1866-99A SK285665B6 (sk) 1997-06-30 1998-06-26 Kryštalické makrolidy, spôsob ich prípravy, farmaceutický prostriedok a ich použitie

Country Status (32)

Country Link
US (1) US6423722B1 (fr)
EP (1) EP0994880B1 (fr)
JP (2) JP3880634B2 (fr)
KR (1) KR100399765B1 (fr)
CN (1) CN1139595C (fr)
AR (1) AR017754A1 (fr)
AT (1) ATE287410T1 (fr)
AU (1) AU739211B2 (fr)
BR (1) BR9810956A (fr)
CA (1) CA2290412C (fr)
CO (1) CO4940463A1 (fr)
CZ (1) CZ297244B6 (fr)
DE (1) DE69828692T2 (fr)
DK (1) DK0994880T3 (fr)
ES (1) ES2236922T3 (fr)
GB (1) GB9713730D0 (fr)
HK (1) HK1028597A1 (fr)
HU (1) HU227755B1 (fr)
ID (1) ID24897A (fr)
IL (1) IL132761A0 (fr)
MY (1) MY118718A (fr)
NO (1) NO312765B1 (fr)
NZ (1) NZ500994A (fr)
PE (1) PE97699A1 (fr)
PL (1) PL192761B1 (fr)
PT (1) PT994880E (fr)
RU (1) RU2219181C2 (fr)
SK (1) SK285665B6 (fr)
TR (1) TR199903189T2 (fr)
TW (1) TW552264B (fr)
WO (1) WO1999001458A1 (fr)
ZA (1) ZA985655B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
ES2335284T3 (es) * 2003-09-03 2010-03-24 Glaxo Group Limited Nuevo procedimiento para preparar derivados de pleuromutilina.
EP1817314A1 (fr) 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Pimecrolimus amorphe non hygroscopique pulverulent
WO2008057511A2 (fr) * 2006-11-06 2008-05-15 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Ascomycine et pimécrolimus ayant des niveaux réduits de desméthylascomycine et de 32-désoxy-32-épichloro-desméthylascomycine respectivement, et leurs procédés de préparation
JP2010512333A (ja) * 2006-12-07 2010-04-22 ヘルシン ヘルスケア ソシエテ アノニム 塩酸パロノセトロンの結晶及び非晶質形
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US10369256B2 (en) 2009-07-10 2019-08-06 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
JP5933434B2 (ja) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 薬剤送達バルーンの製造方法
EP2611476B1 (fr) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Procédé d'enrobage de ballonnets d'administration de médicaments utilisant une mémoire d'enveloppe induite par la chaleur
WO2013022458A1 (fr) * 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Procédés de conversion d'une substance médicamenteuse amorphe en une forme cristalline
WO2013028208A1 (fr) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Dispositif médical comprenant un revêtement médicamenteux cristallin
EP2972258B1 (fr) 2013-03-15 2021-08-04 Biosensors International Group, Ltd. Purification de dérivés de rapamycine
EP3178824A1 (fr) 2015-12-08 2017-06-14 Medichem, S.A. Procédé de préparation de pimecrolimus
KR102592374B1 (ko) * 2017-05-01 2023-10-25 메다 파마 게엠베하 운트 코. 카게 조질의 아스코마이신을 정제된 피메크롤리무스로 전환하는 방법
EP3741367A1 (fr) 2019-05-21 2020-11-25 Premark Pharma GmbH Traitement de maladies oculaires

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
JP2728482B2 (ja) * 1989-01-26 1998-03-18 協和醗酵工業株式会社 マクロライド系抗生物質の精製法
EP0433428B1 (fr) 1989-07-10 1994-10-12 Chemferm V.O.F. Forme de cephradine stable, procede de production de celle-ci, et produits intermediaires utilises
AU640963B2 (en) * 1989-11-09 1993-09-09 MEDA Pharma S.a.r.l Heteroatoms-containing tricyclic compounds
IE910847A1 (en) * 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
EP0480623A1 (fr) * 1990-10-11 1992-04-15 Merck & Co. Inc. Halomacrolides et dérivés ayant une activité immunosuppressive
ES2100291T3 (es) 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
JP3808500B2 (ja) * 1994-02-22 2006-08-09 キューレータズ オブ ディ ユニバーシティ オブ ミズーリ 分離剤としての大環状抗生物質
CA2229718A1 (fr) * 1995-08-24 1997-03-06 David J. Mathre Procede de preparation d'immunosuppresseurs macrolides a base d'imidazolyle
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
HUP0003053A2 (hu) 2001-02-28
NO312765B1 (no) 2002-07-01
JP2001506279A (ja) 2001-05-15
CN1261365A (zh) 2000-07-26
CA2290412A1 (fr) 1999-01-14
KR100399765B1 (ko) 2003-09-29
AR017754A1 (es) 2001-10-24
GB9713730D0 (en) 1997-09-03
WO1999001458A1 (fr) 1999-01-14
DE69828692D1 (de) 2005-02-24
JP4504323B2 (ja) 2010-07-14
CA2290412C (fr) 2009-11-10
PT994880E (pt) 2005-06-30
ES2236922T3 (es) 2005-07-16
JP3880634B2 (ja) 2007-02-14
ATE287410T1 (de) 2005-02-15
BR9810956A (pt) 2000-09-26
NO995909L (no) 1999-12-02
US6423722B1 (en) 2002-07-23
SK186699A3 (en) 2000-05-16
NO995909D0 (no) 1999-12-02
HK1028597A1 (en) 2001-02-23
NZ500994A (en) 2001-08-31
CZ297244B6 (cs) 2006-10-11
JP2006151999A (ja) 2006-06-15
ID24897A (id) 2000-08-31
HUP0003053A3 (en) 2003-03-28
AU739211B2 (en) 2001-10-04
CZ474099A3 (cs) 2000-04-12
ZA985655B (en) 1998-12-30
RU2219181C2 (ru) 2003-12-20
PL192761B1 (pl) 2006-12-29
PL336719A1 (en) 2000-07-03
EP0994880B1 (fr) 2005-01-19
HU227755B1 (en) 2012-02-28
KR20010020423A (ko) 2001-03-15
TW552264B (en) 2003-09-11
MY118718A (en) 2005-01-31
DK0994880T3 (da) 2005-05-30
DE69828692T2 (de) 2006-01-12
AU8540998A (en) 1999-01-25
PE97699A1 (es) 1999-10-29
IL132761A0 (en) 2001-03-19
CN1139595C (zh) 2004-02-25
TR199903189T2 (xx) 2000-06-21
EP0994880A1 (fr) 2000-04-26
CO4940463A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
JP4504323B2 (ja) 結晶性マクロライドおよびその調製方法
CN102985423B (zh) 嘌呤衍生物的结晶形式
EA015677B1 (ru) СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
US20230357322A1 (en) Method of manufacturing a pharmaceutical composition
JP2023532787A (ja) 結晶形態のウパダシチニブ（ｕｐａｄａｃｉｔｉｎｉｂ）、その調製方法及びその使用
TW202138346A (zh) ７ｈ－苯並［７］輪烯－２－羧酸衍生物之晶形
CN113166169A (zh) Mcl-1抑制剂的新晶型，其制备方法和含有它们的药物组合物
EP2397473A1 (fr) Anacetrapib stable fortement cristallin
MXPA99011294A (es) Macrolidos cristalinos y proceso para su preparacion
MXPA04010284A (es) Polimorfo de derivado de ascomicina.
TWI707851B (zh) 哌嗪化合物的新穎結晶
US20070066656A1 (en) Novel stable polymorphic forms of an anticonvulsant
WO2023139313A1 (fr) Nouvelles formes de sel de sulfate d'agoniste d'adrénorécepteur alpha-2 à structure isochroman-imidazole
CN112574330A (zh) 一种舒更葡糖钠晶型
US20030203931A1 (en) Polymorph of a pharmaceutical

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: MEDA PHARMA S.A.R.L., LUXEMBOURG, LU

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130222

MK4A Expiry of patent

Expiry date: 20180626